Formycon AGHAM:FYB +1.46%56 Days Payable is 252.03 as of Dec. 2025, which is 289% above its 10-year median of 64.80. GuruFocus rates HAM:FYB with a GF Score™ of 56/100 and a GF Value™ of €37.06 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 702 Biotechnology companies, Formycon AG ranks better than 63.96% on this metric.
The historical rank and industry rank for Formycon AG's Days Payable or its related term are showing as below:
HAM:FYB'
s Days Payable Range Over the Past 10 Years
Min: 33.82 Med: 64.8 Max: 203.56
Current: 203.56
During the past 13 years, Formycon AG's highest Days Payable was 203.56. The lowest was 33.82. And the median was 64.80.
HAM:FYB's Days Payable is ranked better than 63.96% of 702
companies
in the Biotechnology industry
Industry Median: 113.1
vs HAM:FYB: 203.56
Formycon AG's Days Payable
increased
from Dec. 2024 (105.09) to Dec. 2025 (252.03).
It may suggest that Formycon AGdelayed paying its suppliers.
Formycon AG Days Payable Related Terms
Formycon AG Days Payable Historical Data
* Premium members only.
The historical data trend for Formycon AG's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:FYB vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Formycon AG's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Formycon AG Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Formycon AG's Days Payable distribution charts can be found below:
* The bar in red indicates where Formycon AG's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Formycon AG's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Formycon AG (HAM:FYB) has a Days Payable of 252.03 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Formycon AG and its competitors. This is 289% above median its historical median of 64.80. Over the past decade, Formycon AG's Days Payable has ranged from 33.82 to 203.56. According to the industry distribution chart, Formycon AG ranks #253 out of 702 companies in the Biotechnology industry, placing it in the top 36%.
Is Formycon AG's Days Payable too high?
Formycon AG's current Days Payable of 252.03 is 289% above median its 10-year median of 64.80. Over the past 10 years, this metric has ranged from a low of 33.82 to a high of 203.56. The Biotechnology industry median Days Payable is 113.10. Formycon AG's value of 252.03 is 122.8% above this industry median. Based on the distribution chart, Formycon AG ranks #253 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Formycon AG has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Formycon AG's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Formycon AG ranks #253 out of 702 companies for Days Payable. This puts Formycon AG in the upper half of its industry. The industry median Days Payable is 113.10. Formycon AG's value of 252.03 is 122.8% above this benchmark. Historically, Formycon AG's own Days Payable has ranged from 33.82 to 203.56 over the past decade. While the company's 10-year median is 64.80 vs. the industry median of 113.10, Formycon AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Formycon AG's current Days Payable of 252.03 is 122.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Formycon AG and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Formycon AG's current Days Payable is 252.03, which is 289% above median its own 10-year median of 64.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Formycon AG stock overvalued right now?
Based on GuruFocus' analysis, Formycon AG (HAM:FYB) is currently considered Possible Value Trap. The stock's GF Value™ is €37.06, compared to a current price of €19.40 — trading 47.7% below its estimated fair value. The current Days Payable is 252.03, which is 289% above median its 10-year median of 64.80 and 122.8% above the Biotechnology industry median of 113.10. Formycon AG's overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Formycon AG (HAM:FYB), the current Days Payable is 252.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Formycon AG (HAM:FYB) Overvalued in 2026?
Based on GuruFocus' analysis, Formycon AG stock appears to be undervalued.
The current stock price of €19.40 is trading 47.7% below its estimated GF Value™ of €37.06.
GuruFocus considers Formycon AG to be Possible Value Trap.
Key valuation signals for HAM:FYB:
Days Payable: 252.03 (289% above median its 10-year median of 64.80)
GF Value™: €37.06 vs. price of €19.40 (47.7% below fair value)
Industry Position: 122.8% above the Biotechnology median (#253 of 702)
No single metric tells the full story. See the HAM:FYB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formycon AG is an independent developer of high-quality biosimilars, which are follow-on products to biopharmaceutical drugs. The Company focuses on expanding and further developing its scalable biosimilar platform, which includes approved and pipeline products across ophthalmology, immunology, and immuno-oncology. Its key products include FYB201 (ranibizumab), FYB202 (ustekinumab), FYB203 (aflibercept), FYB206 (pembrolizumab), and FYB208 (dupilumab), along with additional biosimilar candidates in various stages of development. The Company generates maximum revenue from Switzerland.
56GF Score
Get the complete analysis for HAM:FYB
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:FYB has been successfully added to your 
